Comparison · NCT03018249-eded1985
Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA vs Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat: Percentage of Participants With a Histologic Response
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA vs Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat: Percentage of Participants With a Histologic Response. Trial comparisons, record NCT03018249-eded1985. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03018249-eded1985
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.727 | 0.518 | 0.868 | wilson | |
| Risk in group 2 | 0.7 | 0.481 | 0.855 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0273 | -0.232 | 0.288 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.04 | 0.707 | 1.53 | log | |
| Odds ratio, group 1 over group 2 | 1.14 | 0.299 | 4.36 | log | |
Number needed to treat, for one more participant with the outcome on Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA than on Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat | 36.7 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm I (Medroxyprogesterone Acetate, Hysterectomy) MPA | Patients receive medroxyprogesterone acetate IM on day 1 and undergo hysterectomy between days 21-24. | 16 | 22 | OG000 |
| Group 2 | Arm II (Medroxyprogesterone Acetate, Entinostat, Hysterectomy) MPA and Entinostat | Medroxyprogesterone acetate IM on day 1 and entinostat PO on days 1, 8, and 15. Followed by hysterectomy between days 21-24. | 14 | 20 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Percentage of Participants With a Histologic Response
- Description
Pre- and post-treatment slides for each patient were evaluated in pairs for complete or partial histologic response by one reviewer. Pre- and post-treatment slides for each patient were evaluated in pairs for complete or partial histologic response by one reviewer. A histologic response was defined as either the absence of identifiable adenocarcinoma in the hysterectomy specimen section (complete) or, subjectively, as the presence of a complex proliferation of glands that retain the architectural characteristics of adenocarcinoma, but with features of secretion, decreased nuclear stratification, or the presence of eosinophilic, squamous or mucinous metaplasia, when this was absent in the initial sample (partial).
- Time frame
- Specimens were collected at initial diagnostic biopsy and at hysterectomy on day 21-24 and analyzed in batch.
- Population
Randomized, treated, evaluable pre and post treatment specimen available. There were 2 participants in each reporting group who withdrew consent prior to treatment; no specimens were submitted for these patients. There was one participant with an inevaluable pre-treatment slide. There were two additional patients with insufficient tumor post-treatment and no slides were submitted; one in each reporting group. There was one additional patient with no specimens submitted in reporting group 2.
Source ClinicalTrials.gov
Trial
- Title
- Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial Cancer
- NCT number
- NCT03018249
- Phases
- EARLY_PHASE1
- Conditions
- FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 3 Endometrial Endometrioid Adenocarcinoma
- Interventions
- Entinostat, Hysterectomy, Laboratory Biomarker Analysis, Medroxyprogesterone Acetate
- Lead sponsor
- National Cancer Institute (NCI)
- Results first posted
- 2021-06-02
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03018249?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03018249-eded1985